Arecor Therapeutics PLC TETRIS PHARMA SERVICE AGREEMENT WITH SYNEOS HEALTH

TIDMAREC

Arecor Therapeutics PLC

12 December 2022

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

TETRIS PHARMA SIGNS SERVICE AGREEMENT WITH SYNEOS HEALTH

Cambridge, UK, 12 December 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that subsidiary company, Tetris Pharma Ltd has signed a service agreement with Syneos Health(R) (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma's commercial platform across Europe.

See full Tetris Pharma announcement below:

Tetris Pharma signs service agreement with Syneos Health

Partnership to support Tetris Pharma roll-out of Ogluo(R) across Europe

12 December 2022 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC), today announces that it has signed a service agreement with Syneos Health(R) (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success, to support the build out of Tetris Pharma's commercial platform across Europe.

Through this partnership, Syneos Health will provide commercial support through an outsourced contract sales services to accelerate healthcare practitioner awareness of Tetris Pharma's flagship product, Ogluo(R), for people living with diabetes across initial launch territories.

Dr. Shafiq Choudhary, Managing Director, Tetris Pharma, commented:

"Following the recent launch of Ogluo(R) (glucagon prefilled autoinjector pen) in Germany, we are focused on continuing its accelerated roll-out across Europe. Syneos Health was one of several potential partners that were evaluated during the process of partnering with an organisation that would provide a multitude of commercial options to help establish the product across Europe. Partnering with Syneos Health, a leader in clinical research, medical affairs, and commercialisation services for the pharmaceutical industry, is key to building our reputation as specialists in the marketing, sales, and distribution of commercial-stage specialty hospital products across the UK and Europe."

Enquiries:

Tetris Pharma

   Shafiq Choudhary            +44 (0)1628 337579

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage specialty pharmaceutical company with expertise in registering, marketing, sales and the distribution of speciality hospital products across the UK and Europe. Our experienced team has a proven history of building and growing sales. Having secured distribution rights for already licensed products across Europe, we have a portfolio of niche injectable products including Ogluo(R) , a ready-to-use glucagon for emergency use to treat hypoglycaemia. Ogluo prescribing information can be found here. We collaborate with partners to provide patients with effective treatments and quality healthcare by ensuring we deliver accountability, partnership and performance.

For further information, please visit tetrispharma.com

-ENDS-

For more information, please contact:

 
 Arecor Therapeutics plc                  www.arecor.com 
 Dr Sarah Howell, Chief Executive         Tel: +44 (0) 1223 426060 
  Officer                                  Email: info@arecor.com 
 
 Susan Lowther, Chief Financial Officer   Tel: +44 (0) 1223 426060 
                                           Email: info@arecor.com 
 
 Mo Noonan, Communications                Tel: +44 (0) 7876 444977 
                                           Email: mo.noonan@arecor.com 
 
 Panmure Gordon (UK) Limited (NOMAD       Tel: +44 (0) 20 7886 2500 
  and Broker) 
  Freddy Crossley, Emma Earl (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking) 
 
 Consilium Strategic Communications       Tel: +44 (0) 20 3709 5700 
  Chris Gardner, David Daley, Angela       Email: arecor@consilium-comms.com 
  Gray

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat(TM), we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat(TM) platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRATTBMTMTMBBMT

(END) Dow Jones Newswires

December 12, 2022 05:04 ET (10:04 GMT)

Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Jun 2024 to Jul 2024